Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 703-709

  Milano, Filippo ^a,b   Au, Margaret A ^c,d   Boeckh, Michael J ^a,c   Deeg, H Joachim ^a,c   Chien, Jason W ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Bone marrow transplantation; Pulmonary complications; Thymoglobulin

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; AIRWAY OBSTRUCTION; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAFT VERSUS HOST REACTION; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; RESPIRATORY FAILURE; SCHOOL CHILD; TOTAL LUNG CAPACITY;

ADMINISTRATION, ORAL; ADULT; ANIMALS; ANTILYMPHOCYTE SERUM; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PULMONARY DIFFUSING CAPACITY; RABBITS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE; VITAL CAPACITY;

EID: 79954585756     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.08.012     Document Type: Article

References (39)

1. Breuer R., Lossos I.S., Berkman N., et al. Pulmonary complications of bone marrow transplantation. Respir Med 1993, 87:571-579.
2. Cordonnier B., Bierling J.F., Vernant J.P., et al. Pulmonary complications occurring after allogeneic bone marrow transplantation: a study of 130 consecutive transplanted patients. Cancer 1986, 58:1047-1054.
3. Beinert T., Dull T., Kolb H., et al. Late pulmonary impairment following allogeneic bone marrow transplantation. Eur J Med Res 1996, 1:343-348.
4. Soubani A.O., Miller K.B., Hassoun P.M. Pulmonary complications of bone marrow transplantation. Chest 1996, 109:1066-1077.
5. Patriarca F., Sperotto A., Fanin R., et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant 2004, 33:751-758.
6. Yoshihara S., Yanik G., Cooke K.R., et al. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:749-759.
7. Chien J.W., Martin P.J., Gooley T.A., et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2003, 168:208-214.
8. Chien J.W., Maris M.B., Clark J.G., et al. Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:288-296.
9. Santo Tomas L.H., Loberiza F.R., Horowitz M.M., et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation for leukemia. Chest 2005, 128:153-161.
10. Sakaida E., Nakaseko C., Nishimura M., et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood 2003, 102:4236-4242.
11. Ditschkowski M., Elmaagacli A.H., Beelen D.W., et al. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica 2007, 92:558-561.
12. Yoshihara S., Tateishi U., Mineishi S., et al. Lower incidence of bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant 2005, 35:1195-1200.
13. Freudenberger T.D., Madtes D.K., Hackman R.C., et al. Association between acute and chronic graft versus host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplanst. Blood 2003, 102:3822-3828.
14. Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006, 12:573-584.
15. Bacigalupo A. Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol 2005, 12:457-462.
16. Bacigalupo A., Bosi A., Bruzzi P., et al. Antithymocyte globulin (ATG) prevents severe acute graft versus host disease (GVHD) in unrelated donor transplants: two randomized studies from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant April 2001, 27. Supplement 1, S170-S179.
17. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: two randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
18. Bacigalupo A., Lamparelli T., Bosi A., et al. Thymoglobulin prevents chronic graft-versus-host-disease, chronic lung dysfunction, and late transplanted-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
19. Nichols W.G., Erdman D.D., Boeckh M., et al. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004, 10:58-64.
20. Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
21. Przepiorka D., Smith T.L., Folloder J., et al. Risk factors for acute graft versus host disease after allogeneic blood stem cell transplantation. Blood 1999, 94:1465-1470.
22. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host-disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
23. American Thoracic Society Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991, 144:1202-1218.
24. Crapo R., Morris A., Gardner R. Reference spirometric values using techniques and equipment that meet ATS reccomendations. Am Rev Respir Dis 1981, 123:659-664.
25. Parimon T., Madtes D.K., Chien J.W., et al. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med 2005, 172:384-390.
26. Ramirez-Sarmiento A., Orozco-Levi M., Chien J.W., et al. Influence of pretransplantation restrictive lung disease on allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant 2010, 16:199-206.
27. Williams K.M., Chien J.W., Gladwin M.T., et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
28. Byrne J.L., Stainer C., Cull G., et al. The effect of serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host-disease and outcome following unrelated donor bone marrow transplantation for leukemia. Bone Marrow Transplant 2000, 25:411-417.
29. Storb R., Etzioni R., Anasetti C., et al. Cyclophoshamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood 1994, 84:941-949.
30. Chien J.W., Martin P.J., Clark A.G., et al. Implications of early airflow decline after myeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004, 33:759-764.
31. Cooper J.A.D., White D.A., Matthay R.A. Drug-induced pulmonary disease, part 1: cytotoxic drugs. Am Rev Respir Dis 1986, 133:321-340.
32. Vergnon J.M., Bouchero S., Emonot A., et al. Interstitial pneumopathies caused by busulfan: histologic developmental and bronchoalveolar lavage analysis of 3 cases. Rev Med Intern 1998, 9:377-383.
33. Burns W.A., McFarland W., Matthews M.J. Busulfan-induced pulmonary disease: report of a case and review of the literature. Am Rev Respir Dis 1970, 101:408-413.
34. Barret A. Relationship of irradiation to pulmonary complications. Exp Hematol 1984, 12:6-7.
35. Weshler Z., Breuer R., Or R., et al. Interstitial pneumonitis after total body irradiation: effects of total lung shielding. Br J Haematol 1990, 74:61-64.
36. Schultz K.R., Green G.J., Wensley J.L., et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994, 9:3212-3220.
37. Remberger M., Mattsson J., Ringden O. Polyclonal anti-T cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatr Transplant 2001, 5:285-292.
38. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
39. Erard V, Chien JW, Boeckh M, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 193;12:1619-1625.